IN THE CLAIMS

Please cancel claims 15 and 17 without prejudice to their presentation in a continuation or divisional application.

Please replace claim 1 with the correspondingly numbered claim:

1 (Amended). A compound of the formula:

$$A_0\text{-}A_1\text{-}A_2\text{-}A_3\text{-}A_4\text{-}A_5\text{-}A_6\text{-}A_7\text{-}A_8\text{-}A_9\text{-}A_{10}$$

or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein:

A_0 is an acyl group selected from:

(1) $R\text{-}(CH_2)_n\text{-}C(O)\text{-}$; wherein n is an integer from 0 to 8 and R is selected from hydroxyl; methyl; N-acetylamino; methoxyl; carboxyl; cyclohexyl optionally containing a one or two double bonds and optionally substituted with one to three hydroxyl groups; and a 5- or 6-membered ring aromatic or nonaromatic ring optionally containing one or two heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the ring is optionally substituted with a moiety selected from alkyl, alkoxy, and halogen; and

(2) $R^1\text{-}CH_2CH_2\text{-}(OCH_2CH_2O)_p\text{-}CH_2\text{-}C(O)\text{-}$; wherein R^1 is selected from hydrogen, alkyl, and N-acetylamino, and p is an integer from 1 to 8;

A_1 is an amino acyl residue selected from:

(1) alanyl,
(2) asparaginyl,
(3) citrullyl,
(4) glutaminyl,
(5) glutamyl,
(6) N-ethylglycyl,
(7) methionyl,
(8) N-methylalanyl,

(9) prolyl,
(10) pyro-glutamyl,
(11) sarcosyl,
(12) seryl,
(13) threonyl,
(14) -HN-$(CH_2)_q$-C(O)-, wherein q is 1 to 8, and
(15) -HN-CH_2CH_2-$(OCH_2CH_2O)_r$-CH_2-C(O)-, wherein r is 1 to 8;

A_2 is an amino acyl residue selected from:

(1) alanyl,
(2) asparaginyl,
(3) aspartyl,
(4) glutaminyl,
(5) glutamyl,
(6) leucyl,
(7) methionyl,
(8) phenylalanyl,
(9) prolyl,
(10) seryl,
(11) -HN-$(CH_2)_q$-C(O)-, wherein q is 1 to 8,
(12) -HN-CH_2CH_2-$(OCH_2CH_2O)_r$-CH_2-C(O)-, wherein r is 1 to 8, and
(13) glycyl;

A_3 is an amino acyl residue selected from:

(1) alanyl,
(2) asparaginyl,
(3) citrullyl,
(4) cyclohexylalanyl,
(5) cyclohexylglycyl,
(6) glutaminyl,
(7) glutamyl,
(8) glycyl,
(9) isoleucyl,
(10) leucyl,
(11) methionyl,
(12) norvalyl,

(13) phenylalanyl,
(14) seryl,
(15) *t*-butylglycyl,
(16) threonyl,
(17) valyl,
(18) penicillaminyl, and
(19) cystyl;

A_4 is an amino acyl residue of L or D configuration selected from:

(1) allo-isoleucyl,
(2) glycyl,
(3) isoleucyl,
(4) prolyl,
(5) dehydroleucyl,
(6) D-alanyl,
(7) D-3-(naphth-1-yl)alanyl,
(8) D-3-(naphth-2-yl)alanyl,
(9) D-(3-pyridyl)-alanyl,
(10) D-2-aminobutyryl,
(11) D-allo-isoleucyl,
(12) D-allo-threonyl,
(13) D-allylglycyl,
(14) D-asparaginyl,
(15) D-aspartyl,
(16) D-benzothienyl,
(17) D-3-(4,4'-biphenyl)alanyl,
(18) D-chlorophenylalanyl,
(19) D-3-(3-trifluoromethylphenyl)alanyl,
(20) D-3-(3-cyanophenyl)alanyl,
(21) D-3-(3,4-difluorophenyl)alanyl,
(22) D-citrullyl,
(23) D-cyclohexylalanyl,
(24) D-cyclohexylglycyl,
(25) D-cystyl,
(26) D-cystyl(*S*-*t*-butyl),

(27) D-glutaminyl,
(28) D-glutamyl,
(29) D-histidyl,
(30) D-homoisoleucyl,
(31) D-homophenylalanyl,
(32) D-homoseryl,
(33) D-isoleucyl,
(34) D-leucyl,
(35) D-lysyl(N-epsilon-nicotinyl),
(36) D-lysyl,
(37) D-methionyl,
(38) D-neopentylglycyl,
(39) D-norleucyl,
(40) D-norvalyl,
(41) D-ornithyl,
(42) D-penicillaminyl,
(43) D-penicillaminyl(acetamidomethyl),
(44) D-penicillaminyl(*S*-benzyl),
(45) D-phenylalanyl,
(46) D-3-(4-aminophenyl)alanyl,
(47) D-3-(4-methylphenyl)alanyl,
(48) D-3-(4-nitrophenyl)alanyl,
(49) D-3-(3,4-dimethoxyphenyl)alanyl,
(50) D-3-(3,4,5-trifluorophenyl)alanyl,
(51) D-prolyl,
(52) D-seryl,
(53) D-seryl(*O*-benzyl),
(54) D-*t*-butylglycyl,
(55) D-thienylalanyl,
(56) D-threonyl,
(57) D-threonyl(*O*-benzyl),
(58) D-tryptyl,
(59) D-tyrosyl(*O*-benzyl),
(60) D-tyrosyl(*O*-ethyl),

(61) D-tyrosyl, and

(62) D-valyl;

A_5 is an amino acyl residue of L or D configuration selected from:

(1) alanyl,

(2) (3-pyridyl)alanyl,

(3) 3-(naphth-1-yl)alanyl,

(4) 3-(naphth-2-yl)alanyl,

(5) allo-threonyl,

(6) allylglycyl,

(7) glutaminyl,

(8) glycyl,

(9) histidyl,

(10) homoseryl,

(11) isoleucyl,

(12) lysyl(N-epsilon-acetyl),

(13) methionyl,

(14) norvalyl,

(15) octylglycyl,

(16) ornithyl,

(17) 3-(4-hydroxymethylphenyl)alanyl,

(18) prolyl,

(19) seryl,

(20) threonyl,

(21) tryptyl,

(22) tyrosyl,

(23) D-allo-threonyl,

(24) D-homoseryl,

(25) D-seryl,

(26) D-threonyl,

(27) penicillaminyl, and

(28) cystyl;

A_6 is an amino acyl residue of L or D configuration selected from:

(1) alanyl,

(2) 3-(naphth-1-yl)alanyl,

(3) 3-(naphth-2-yl)alanyl,
(4) (3-pyridyl)alanyl,
(5) 2-aminobutyryl,
(6) allylglycyl,
(7) arginyl,
(8) asparaginyl,
(9) aspartyl,
(10) citrullyl,
(11) cyclohexylalanyl,
(12) glutaminyl,
(13) glutamyl,
(14) glycyl,
(15) histidyl,
(16) homoalanyl,
(17) homoleucyl,
(18) homoseryl,
(19) isoleucyl,
(20) leucyl,
(21) lysyl(N-epsilon-acetyl),
(22) lysyl(N-epsilon-isopropyl),
(23) methionyl(sulfone),
(24) methionyl(sulfoxide),
(25) methionyl,
(26) norleucyl,
(27) norvalyl,
(28) octylglycyl,
(29) phenylalanyl,
(30) 3-(4-carboxyamidephenyl)alanyl,
(31) propargylglycyl,
(32) seryl,
(33) threonyl,
(34) tryptyl,
(35) tyrosyl,
(36) valyl,

(37) D-3-(naphth-1-yl)alanyl,
(38) D-3-(naphth-2-yl)alanyl,
(39) D-glutaminyl,
(40) D-homoseryl,
(41) D-leucyl,
(42) D-norvalyl,
(43) D-seryl,
(44) penicillaminyl, and
(45) cystyl;

A_7 is an amino acyl residue of L or D configuration selected from:

(1) alanyl,
(2) allylglycyl,
(3) aspartyl,
(4) citrullyl,
(5) cyclohexylglycyl,
(6) glutamyl,
(7) glycyl,
(8) homoseryl,
(9) isoleucyl,
(10) allo-isoleucyl
(11) leucyl,
(12) lysyl(N-epsilon-acetyl),
(13) methionyl,
(14) 3-(naphth-1-yl)alanyl,
(15) 3-(naphth-2-yl)alanyl,
(16) norvalyl,
(17) phenylalanyl,
(18) prolyl,
(19) seryl,
(20) *t*-butylglycyl,
(21) tryptyl,
(22) tyrosyl,
(23) valyl,
(24) D-allo-isoleucyl,

(25) D-isoleucyl,

(26) penicillaminyl, and

(27) cystyl;

A_8 is an amino acyl residue selected from:

(1) 2-amino-4-[(2-amino)-pyrimidinyl]butanoyl,

(2) alanyl(3-guanidino),

(3) alanyl[3-pyrrolidinyl(2-N-amidino)],

(4) alanyl[4-piperidinyl(N-amidino)],

(5) arginyl,

(6) arginyl($N^G N^{G'}$diethyl),

(7) citrullyl,

(8) 3-(cyclohexyl)alanyl(4-N'-isopropyl),

(9) glycyl[4-piperidinyl(N-amidino)],

(10) histidyl,

(11) homoarginyl,

(12) lysyl,

(13) lysyl(N-epsilon-isopropyl),

(14) lysyl(N-epsilon-nicotinyl),

(15) norarginyl,

(16) ornithyl(N-delta-isopropyl),

(17) ornithyl(N-delta-nicotinyl),

(18) ornithyl[N-delta-(2-imidazolinyl)],

(19) [(4-amino(N-isopropyl)methyl)phenyl]alanyl,

(20) 3-(4-guanidinophenyl)alanyl, and

(21) 3-(4-amino-N-isopropylphenyl)alanyl;

A_9 is an amino acyl residue of L or D configuration selected from:

(1) 2-amino-butyryl,

(2) 2-amino-isobutyryl,

(3) homoprolyl,

(4) hydroxyprolyl,

(5) isoleucyl,

(6) leucyl,

(7) phenylalanyl,

(8) prolyl,

(9) seryl,
(10) *t*-butylglycyl,
(11) 1,2,3,4-tetrahydroisoquinoline-3-carbonyl,
(12) threonyl,
(13) valyl,
(14) D-alanyl, and
(15) D-prolyl; and

A_{10} is a hydroxyl group or an amino acid amide is selected from:

azaglycylamide,
D-alanylamide,
D-alanylethylamide,
glycylamide,
glycylethylamide,
sarcosylamide,
serylamide,
D-serylamide,
a group represented by the formula

$$-NH-(CH_2)_s-\underset{\displaystyle R^2}{\overset{|}{C}}HR^3$$

, and
a group represented by the formula $-NH-R^4$;

wherein:

s is an integer selected from 0 to 8,

R^2 is selected from hydrogen, alkyl, and a 5- to 6-membered cycloalkyl ring;

R^3 is selected from hydrogen, hydroxy, alkyl, phenyl, alkoxy, and a 5- to 6-membered ring optionally containing from one to two heteroatoms selected from oxygen, nitrogen, and sulfur, provided that s is not zero when R^3 is hydroxy or alkoxy; and

R^4 is selected from hydrogen, hydroxy, and a 5- to 6-membered cycloalkyl ring.

Please add the following new claims:

18 (New). A compound, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH$_2$CH$_3$, and
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH$_2$CH$_3$.

19 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$.

20 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$.

21 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH$_2$CH$_3$.

22 (New). The compound, or pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, which is N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH$_2$CH$_3$.

23 (New). A composition comprising a compound, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, selected from the group consisting of
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$,
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$,
N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH$_2$CH$_3$, and
N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH$_2$CH$_3$,
and a pharmaceutically acceptable carrier.

24 (New). A composition comprising
N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

25 (New). A composition comprising
N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

26 (New). A composition comprising

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

27 (New). A composition comprising N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

28 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising a compound, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, selected from the group consisting of

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-Ile-Arg-ProNHCH$_2$CH$_3$, and

N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH$_2$CH$_3$,

and a pharmaceutically acceptable carrier.

29 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

30 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-ProNHCH$_2$CH$_3$, or a pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.

31 (New). A composition for the treatment of a disease selected from cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical intervention, macular degeneration, and diabetic retinopathy comprising